# US 2013/0252831 A1 · Method of diagnosing early stage non-small cell lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252831 A1
- Document ID: US20130252831A1
- Status: Published application
- Kind: A1
- Application number: 13/891,433
- Filed: 2013-05-10
- Published: 2013-09-26
- Earliest claimed: 2010-11-10
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Inventors: Dung-Tsa Chen
- Web page: https://patentgrep.com/patent/US20130252831A1

## CPC

- C12N 15/1089: {Design, preparation, screening or analysis of libraries using computer algorithms}
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57515: of the breast
- G01N 33/5752: of the lungs
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A “malignancy-risk” (MR) gene signature score was developed with abundant proliferative genes using principal component analysis. This MR gene signature was shown to be a predictive and prognostic factor of overall survival in early-stage NSCLC. The malignancy-risk signature showed a significant association with OS, with poor survival seen in patients having a higher MR score and better survival seen in patients having a low MR score. As a prognostic factor, the MR gene signature showed a positive correlation with TNM stage, histologic grade, and smoking status. Combination of the MR signature with each clinical parameter often showed the best survival in the low MR group with good clinical outcome. The MR gene profile, tested with a PCA scoring method, discriminated overall survival in lung cancer patients was a predictor independent of pathological staging and other clinical parameters.

## Claims

### Claim 1

A method of diagnosing cancer comprising:
obtaining a sample tissue;
obtaining a malignancy-risk score, wherein the malignancy-risk score is formed by
collecting at least one gene expression level;
weighting the expression level; and
applying the least one gene expression level and weighting the expression level to the following formula Σwixi, where xi represents gene i expression level wi is the corresponding weight (loading coefficient);
wherein the malignancy-risk score is indicative of clinical diagnosis of the sample tissue for cancer.

### Claim 2 (depends on 1)

The method of claim 1, further comprising calculating gene expression values using the robust multi-array average algorithm.

### Claim 3 (depends on 1)

The method of claim 1, further comprising using a probe set to detect the at least one gene expression level for lung cancer or breast cancer.

### Claim 4 (depends on 1)

The method of claim 1, further comprising analysing at least one clinical variable in concert with the malignancy-risk score, wherein the at least one clinical variable is TNM stage, grade, histologic grade, or smoking history.

### Claim 5 (depends on 4)

The method of claim 4, wherein the TNM stage variables analyzed are pathologic N stage or pathologic T stage.

### Claim 6 (depends on 4)

The method of claim 4, wherein the analysis is conducted using multivariate Cox proportional hazards regression analysis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the at least one gene expression level is from at least one malignancy-risk gene.

### Claim 8 (depends on 1)

The method of claim 1, wherein a low malignancy-risk score correlates with better survival.

### Claim 9

A method of predicting the response of a subject to therapy for lung cancer comprising:
obtaining a sample tissue;
obtaining a malignancy-risk score, wherein the malignancy-risk score is formed by
collecting at least one gene expression level;
weighting the expression level; and
applying the least one gene expression level and weighting the expression level to the following formula Σwixi, where xi represents gene i expression levels wi is the corresponding weight (loading coefficient);
wherein the malignancy-risk score is indicative of clinical diagnosis of the sample tissue for cancer.

### Claim 10 (depends on 9)

The method of claim 9, further comprising calculating gene expression values using the robust multi-array average algorithm.

### Claim 11 (depends on 9)

The method of claim 9, further comprising using a probe set to detect the at least one gene expression level for lung cancer or breast cancer.

### Claim 12 (depends on 9)

The method of claim 9, further comprising analysing at least one clinical variable in concert with the malignancy-risk score, wherein the at least one clinical variable is TNM stage, grade, histologic grade, or smoking history.

### Claim 13 (depends on 12)

The method of claim 12, wherein the TNM stage variables analyzed are pathologic N stage or pathologic T stage.

### Claim 14 (depends on 12)

The method of claim 12, wherein the analysis is conducted using multivariate Cox proportional hazards regression analysis.

### Claim 15 (depends on 9)

The method of claim 9, wherein the at least one gene expression level is from at least one malignancy-risk gene.

### Claim 16 (depends on 9)

The method of claim 9, wherein a low malignancy-risk score correlates with a patient that may benefit from adjuvant chemotherapy (ACT).
